PARP1 and cancer: A lot of well-established target therapies that have been approved for the treatment of other cancers are found to be beneficial in the case of TNBC, including agents that target Poly [ADP ribose] polymerase 1 (PARP1) [6], androgen receptor (AR) [7], vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) under certain circumstances [8].